Cancer patients treated with immunotherapy can safely receive mRNA COVID-19 vaccines, according to JNCCN study

Oct. 17, 2022
Researchers find people undergoing treatment with immune checkpoint inhibitors who receive an mRNA COVID-19 vaccine are not at any greater risk of side effects from the vaccine or the immunotherapy.

New research published in the October 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms the safety of mRNA vaccines in people with cancer undergoing immunotherapy treatment.

The researchers analyzed the frequency of side effects (also referred to as immune-related adverse events, or irAEs) in 408 patients receiving immune checkpoint inhibitor (ICI) therapy between January 16 and March 27, 2021. They found no increase in type, frequency, or severity of side effects from those receiving both immunotherapy and the vaccine at the same time.

NCCN release

ID 204969634 © Sulit Photos | Dreamstime.com
dreamstime_xxl_204969634
ID 340556497 © Svitlana Kuchina | Dreamstime.com
dreamstime_xxl_340556497
ID 76886763 © Jiri Hera | Dreamstime.com
dreamstime_xxl_76886763